首页PRENW • NASDAQ
Prenetics Global Ltd
$0.0099
5月6日, GMT-4 20:15:00 · USD · NASDAQ · 免责声明
昨日收盘价
$0.0094
当日价格范围
$0.0084 - $0.010
年度波幅
$0.0050 - $0.021
市值
6820.29万 USD
平均交易量
1.03万
市场资讯
财务信息
损益表
收入
净收入
(USD)2024年12月年同比变化
收入
1048.81万98.76%
经营支出
2046.94万40.98%
净收入
-1634.17万3.57%
净利润率
-155.8151.49%
每股收益
息税折旧摊销前利润
-1508.56万-39.39%
有效税率
29.73%
总资产
负债总额
(USD)2024年12月年同比变化
现金及短期投资
7078.80万22.84%
总资产
2.14亿-15.97%
负债总额
4222.90万-4.05%
权益总额
1.71亿
发行在外的股份
1298.48万
市净率
0.00
资产回报率
-18.44%
资本回报率
-22.78%
现金净变动
(USD)2024年12月年同比变化
净收入
-1634.17万3.57%
来自运营的现金
投资现金
融资现金
现金净变动
自由现金流
简介
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
成立时间
2014
员工数量
322
一探究竟
您可能感兴趣的股票
此列表是根据近期的搜索内容、关注的证券以及其他活动生成的。了解详情

所有数据和信息均按“原样”提供,仅供个人参考,并非金融建议,不可用于交易目的,亦不可用于提供投资、税务、法律、会计或其他方面的建议。Google 并非投资顾问,也不是金融顾问,并且对此列表中的任何一家公司或该等公司发行的所有证券不发表任何看法、建议或观点。在进行任何交易之前,请先咨询您的经纪人或金融代表,以便核实价格。了解详情
用户还搜索了
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单